Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02413320 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
A Phase 2 study, sponsored by Priyanka Sharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT02413320 is a Phase 2 study that has completed, run by Priyanka Sharma. The registered enrollment target is 101 participants.
The verdict
NCT02413320, a Phase 2 study, has completed, sponsored by Priyanka Sharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of breast cancer cells in women with Stage I, II, or III triple negative breast cancer.
Interventions
- DRUG Cyclophosphamide
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Doxorubicin
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2015-07 |
| Est. Completion | 2020-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02413320
The ClinicalTrials.gov registry entry for NCT02413320 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Priyanka Sharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02413320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02413320 about?
NCT02413320 is a clinical study titled "Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer". Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of breast cancer cells in women with Stage I, II, or III triple negative breast cancer.
What is the current status of trial NCT02413320?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2015-07. Estimated completion is 2020-02-01.
What interventions are being tested in trial NCT02413320?
The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02413320?
This trial is sponsored by Priyanka Sharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.